WallStSmart

Akso Health Group ADR (AHG)vsHenry Schein Inc (HSIC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 89115% more annual revenue ($13.18B vs $14.78M). HSIC leads profitability with a 3.0% profit margin vs 0.0%. HSIC earns a higher WallStSmart Score of 56/100 (C).

AHG

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 7.5
Piotroski: 2/9Altman Z: 7.29

HSIC

Buy

56

out of 100

Grade: C

Growth: 7.3Profit: 5.5Value: 8.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AHG.

HSICUndervalued (+12.5%)

Margin of Safety

+12.5%

Fair Value

$93.39

Current Price

$72.29

$21.10 discount

UndervaluedFair: $93.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
415.8%10/10

Revenue surging 415.8% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.2910/10

Safe zone — low bankruptcy risk

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

AHG4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$807.33M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

HSIC3 concerns · Avg: 3.3/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.023/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 415.8% demonstrates continued momentum.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bear Case : AHG

The primary concerns for AHG are EPS Growth, Market Cap, Profit Margin.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, Profit Margin, Debt/Equity. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

AHG profiles as a hypergrowth stock while HSIC is a value play — different risk/reward profiles.

HSIC carries more volatility with a beta of 0.85 — expect wider price swings.

AHG is growing revenue faster at 415.8% — sustainability is the question.

HSIC generates stronger free cash flow (338M), providing more financial flexibility.

Bottom Line

HSIC scores higher overall (56/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and integrated patient care services. With a specialization in advanced health technologies, the company is well-positioned to tap into growth opportunities in telehealth and personalized medicine, bolstered by a strong commitment to research and development. Its robust business model and dedication to quality, supported by a skilled team of professionals, make Akso Health Group an appealing investment for institutional investors aiming to navigate the transformative landscape of healthcare.

Visit Website →

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?